Tony Bazi1, Satoru Takahashi2, Sharif Ismail3, Kari Bø4, Alejandra M Ruiz-Zapata5, Jonathan Duckett6, Dorothy Kammerer-Doak7. 1. Department of Obstetrics and Gynecology, Faculty of Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon. tb14@aub.edu.lb. 2. Department of Urology, Nihon University School of Medicine, Tokyo, Japan. 3. Brighton and Sussex Medical School, Brighton and Sussex University Hospitals NHS Trust, Brighton, England, UK. 4. Norwegian School of Sport Sciences, Oslo, Norway. 5. Department of Obstetrics and Gynecology, Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Directorate of Women's Health, Medway NHS Foundation Trust, Gillingham, UK. 7. Women's Pelvic Specialty Care of New Mexico, University of New Mexico Hospital, Albuquerque, NM, USA.
Abstract
INTRODUCTION AND HYPOTHESIS: Pelvic floor disorders (PFD), including urinary incontinence, anal incontinence, and pelvic organ prolapse, are common and have a negative effect on the quality of life of women. Treatment is associated with morbidity and may not be totally satisfactory. Prevention of PFDs, when possible, should be a primary goal. The purpose of this paper is to summarise the current literature and give an evidence-based review of the prevention of PFDs METHODS: A working subcommittee from the International Urogynecological Association (IUGA) Research and Development (R&D) Committee was formed. An initial document addressing the prevention of PFDs was drafted, based on a review of the English-language literature. After evaluation by the entire IUGA R&D Committee, revisions were made. The final document represents the IUGA R&D Committee Opinion on the prevention of PFDs. RESULTS: This R&D Committee Opinion reviews the literature on the prevention of PFDs and summarises the findings with evidence-based recommendations. CONCLUSIONS: Pelvic floor disorders have a long latency, and may go through periods of remission, thus making causality difficult to confirm. Nevertheless, prevention strategies targeting modifiable risk factors should be incorporated into clinical practice before the absence of symptomatology.
INTRODUCTION AND HYPOTHESIS: Pelvic floor disorders (PFD), including urinary incontinence, anal incontinence, and pelvic organ prolapse, are common and have a negative effect on the quality of life of women. Treatment is associated with morbidity and may not be totally satisfactory. Prevention of PFDs, when possible, should be a primary goal. The purpose of this paper is to summarise the current literature and give an evidence-based review of the prevention of PFDs METHODS: A working subcommittee from the International Urogynecological Association (IUGA) Research and Development (R&D) Committee was formed. An initial document addressing the prevention of PFDs was drafted, based on a review of the English-language literature. After evaluation by the entire IUGA R&D Committee, revisions were made. The final document represents the IUGA R&D Committee Opinion on the prevention of PFDs. RESULTS: This R&D Committee Opinion reviews the literature on the prevention of PFDs and summarises the findings with evidence-based recommendations. CONCLUSIONS:Pelvic floor disorders have a long latency, and may go through periods of remission, thus making causality difficult to confirm. Nevertheless, prevention strategies targeting modifiable risk factors should be incorporated into clinical practice before the absence of symptomatology.
Entities:
Keywords:
IUGA Research and Development Committee Opinion; Obstetric anal sphincter injuries; Pelvic floor disorders; Pelvic organ prolapse; Prevention; Urinary incontinence
Authors: Jennifer M Wu; Catherine A Matthews; Mitchell M Conover; Virginia Pate; Michele Jonsson Funk Journal: Obstet Gynecol Date: 2014-06 Impact factor: 7.661
Authors: Mary K Townsend; Kim N Danforth; Karen L Lifford; Bernard Rosner; Gary C Curhan; Neil M Resnick; Francine Grodstein Journal: Am J Obstet Gynecol Date: 2007-08 Impact factor: 8.661
Authors: Francisco J Orejuela; Rajshi Gandhi; Lauren Mack; Wesley Lee; Haleh Sangi-Haghpeykar; Hans P Dietz; Susan M Ramin Journal: Int Urogynecol J Date: 2018-02-06 Impact factor: 2.894
Authors: Magdalena Piernicka; Monika Błudnicka; Damian Bojar; Jakub Kortas; Anna Szumilewicz Journal: Int J Environ Res Public Health Date: 2022-05-12 Impact factor: 4.614